In this work we provide an experimental workflow of how active enhancers can be identified and experimentally validated.
El desarrollo embrionario es un proceso de múltiples etapas que implica la activación y la represión de muchos genes. Los elementos potenciadores en el genoma se sabe que contribuyen a los tejidos y células de tipo regulación específica de la expresión génica durante la diferenciación celular. Por lo tanto, su identificación y de la investigación es importante para entender cómo se determina el destino celular. La integración de los datos de expresión de genes (por ejemplo, microarrays o RNA-seq) y los resultados de la inmunoprecipitación de la cromatina (CHIP), con base en los estudios de genoma completo (chip-ss) permite la identificación a gran escala de estas regiones reguladoras. Sin embargo, la validación funcional de potenciadores específicas del tipo de célula requiere más in vitro y en los procedimientos experimentales in vivo. A continuación se describe cómo se pueden identificar y validar experimentalmente potenciadores activos. Este protocolo proporciona un flujo de trabajo paso a paso que incluye: 1) la identificación de regiones reguladoras por análisis, 2) la clonación y exper datos chip-ssvalidación imental del potencial regulador putativo de las secuencias genómicas identificadas en un ensayo reportero, y 3) la determinación de potenciador de la actividad in vivo mediante la medición de nivel de transcrito de ARN potenciador. El protocolo que se presenta es suficientemente detallada para ayudar a cualquier persona para establecer este flujo de trabajo en el laboratorio. Es importante destacar que, el protocolo puede ser adaptado fácilmente y utilizado en cualquier sistema de modelo celular.
Development of a multicellular organism requires precisely regulated expression of thousands of genes across developing tissues. Regulation of gene expression is accomplished in large part by enhancers. Enhancers are short non-coding DNA elements that can be bound with transcription factors (TFs) and act from a distance to activate transcription of a target gene1. Enhancers are generally cis-acting and most frequently found just upstream of the transcription start site (TSS), but recent studies also described examples where enhancers were found much further upstream, on the 3′ of the gene or even within the introns and exons2.
There are hundreds of thousands of potential enhancers in the vertebrate genomes1. Recent methods based on chromatin immunoprecipitation (ChIP) provide high-throughput data of the whole genome that can be used for enhancer analysis3-9. Though data obtained by ChIP-seq experiments greatly increases the likelihood to identify cell and tissue-specific enhancers, it is important to keep in mind that detected binding sites do not necessarily identify direct DNA binding and/or functional enhancers. Thus, further functional analysis of newly identified enhancers is indispensable. In this work, we present a basic three-step process of putative active enhancer identification and validation. This includes: 1) selection of putative transcription factor binding sites by bioinformatics analysis of ChIP-seq data, 2) cloning and validation of these regulatory sequences in reporter constructs, and 3) measurement of enhancer RNA (eRNA).
Exposure of embryonic stem (ES) cells to retinoic acid (RA) is frequently used to promote neural differentiation of the pluripotent cells 10. RA exerts its effects by binding to RA receptors (RARα, β, γ) and retinoid X receptors (RXRα, β, γ). RARs and RXRs in a form of heterodimer bind to DNA motifs called RA-response elements, that is typically arranged as direct repeats of AGGTCA sequence (called as half site) and regulate transcription. Ligand-treatment experiments allowed the identification of several retinoic acid regulated genes in ES cells 11,12. However, enhancer elements for many of these genes has not been described yet. To demonstrate how the here-described workflow can be used for enhancer identification and validation we show step-by-step the selection and characterization of two retinoic acid-dependent enhancers in embryonic stem cells.
In recent years, advances in sequencing technology have allowed large-scale predictions of enhancers in many cell types and tissues 7-9. The workflow described above allows one to perform primary characterization of candidate enhancers chosen based on ChIP-seq data. The detailed steps and notes will help anyone to set up a routine enhancer validation in the lab.
The most critical step in the luciferase reporter assay is the transfection efficiency. It is recommended to include a GFP…
The authors have nothing to disclose.
The authors would like to acknowledge Dr. Bence Daniel, Matt Peloquin, Dr. Endre Barta, Dr. Balint L Balint and members of the Nagy laboratory for discussions and comments on the manuscript. L.N is supported by grants from the Hungarian Scientific Research Fund (OTKA K100196 and K111941) and co-financed by the European Social Fund and the European Regional Development Fund and Hungarian Brain Research Program – Grant No. KTIA_13_NAP-A-I/9.
KOD DNA polymerase | Merck Millipore | 71085-3 | for PCR amplification of enhancer from gDNA |
DNeasy Blood & Tissue kit | Qiagen | 69504 | for genomic DNA isolation |
QIAquick PCR Purification kit | Qiagen | 28106 | for PCR product purification |
Gel extraction kit | Qiagen | 28706 | for gel extraction if there are more PCR product |
HindIII | NEB | R3104L | restriction enzyme |
BamHI | NEB | R3136L | restriction enzyme |
FastAP | Thermo Scientific | EF0651 | release of 5'- and 3'-phosphate groups from DNA |
T4 DNA ligase | NEB | M0202 | for ligation |
QIAprep Spin Miniprep kit | Qiagen | 27106 | for plasmid isolation |
DMEM | Gibco | 31966-021 | ES media |
FBS | Hyclone | SH30070.03 | ES media |
MEM Non-Essential Amino Acid | Sigma | M7145 | ES media |
Penicillin-Streptomycin | Sigma | P4333 | ES media |
Beta Mercaptoethanol | Sigma | M6250 | ES media |
FuGENE HD | Promega | E2311 | transfection reagent |
Opti-MEM® I Reduced Serum Medium | Life Technologies | 31985-062 | for transfection |
All-trans retinoic acid | Sigma | R2625 | ligand, for activation of RAR/RXR |
96-well clear plate | Greiner | 655101 | for Beta galactosidase assay |
96-well white plate | Greiner | 655075 | for Luciferase assay |
D-luciferin, potassium salt | Goldbio.com | 115144-35-9 | for Luciferase assay |
ATP salt | Sigma | A7699-1G | for Luciferase assay |
MgSO4x 7H2O | Sigma | 230391-25G | for Luciferase assay |
HEPES | Sigma | H3375-25G | for Luciferase assay |
Na2HPO4 x 7H2O | Sigma | 431478-50G | for Beta galactosidase assay |
NaH2PO4 x H2O | Sigma | S9638-25G | for Beta galactosidase assay |
MgSO4 x 7H2O | Sigma | 230391-25G | for Beta galactosidase assay |
KCl | Sigma | P9541-500G | for Beta galactosidase assay |
ONPG (o-nitrophenyl-β-D-galactosidase) | Sigma | N1127-1G | for Beta galactosidase assay |
TRIzol® | Life Technologies | 15596-026 | RNA isolation |
High-Capacity cDNA Reverse Transcription Kit | Life Technologies | 4368814 | reverse transcription of eRNA |
Rnase-free Dnase | Promega | M6101 | Dnase treatment |
SsoFast Eva Green | BioRad | 750000105 | RT-qPCR mastermix |
CFX384 Touch™ Real-Time PCR Detection System | BioRad | qPCR machine | |
BioTek Synergy 4 microplate reader | BioTek | luminescent counter |